Full-Time
Confirmed live in the last 24 hours
Biotech company focused on drug discovery
Mid
Cambridge, MA, USA
You match the following Relay Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Relay Therapeutics focuses on drug discovery by emphasizing the movement of proteins in its research. The company uses its Dynamo™ platform, which integrates experimental and computational methods, to identify and develop new drugs, particularly for complex diseases that are hard to treat with current therapies. This platform enables Relay to target proteins that have previously been difficult to address, expanding treatment options in areas like precision oncology and genetic diseases. Unlike many competitors, Relay's approach is centered on understanding protein dynamics, which allows for more effective drug development. The company's goal is to create impactful medicines for patients, and it is engaged in clinical trials to ensure the safety and effectiveness of its drug candidates.
Company Size
201-500
Company Stage
IPO
Total Funding
$535M
Headquarters
Cambridge, Massachusetts
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Medical, dental, vision
Life, disability, & FSA
401k
Commuter benefits
Parental leave
Home office stipend
Tuition reimbursement
PTO
Relay Therapeutics has announced it will be laying off about 10% of its workforce, impacting approximately 30 employees, as confirmed by a spokesperson in a statement to BioSpace.
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwritten
Relay Therapeutics announces pricing of public offering of common stock.
Relay Therapeutics announces $200M public offering of 28.5M shares at $7 each. Learn how this biotech firm plans to use the funds and what it means for investors. Closing expected Sept 12.
Relay Therapeutics announces proposed public offering of common stock.